Based on a recent literature review on the use of HDAC inhibitors for the treatment of AD [224], PD [234], ALS [235], and other NDD in animal models, it was found that HDAC inhibitors (HDACi) were able to enhance synaptic plasticity as well as cognitive and motor functions in the animals. This evidence concerns the gene HDAC9 and Parkinson disease.